Skip to Content

Fedratinib improves OS and PFS for patients with myelofibrosis as first-line therapy and after ruxolitinib

Fedratinib is an oral JAK2 inhibitor that improves splenomegaly and symptoms in patients with intermediate or high-risk myelofibrosis – as first-line (1L) treatment or after ruxolitinib-treatment. In this MEDtalk, Claire Harrison, professor of myeloproliferative neoplasms, presents the survival outcomes from the JAKARTA and JAKARTA2 trial.

Claire Harrison

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top